Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy - 08/09/20
Doi : 10.1016/j.jaad.2020.06.999
Zachary E. Holcomb, MD a, Monica Rosales Santillan, MD b, Peyton C. Morss-Walton, BA b, c, Prerna Salian, MPH b, Min Ji Her, PharmD d, Nicole M. Giannotti b, e, Alexa B. Kimball, MD, MPH b, f, Martina L. Porter, MD b, f, ⁎ 
a Harvard Combined Dermatology Residency Program, Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts
b Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
c University of Massachusetts Medical School, Worcester, Massachusetts
d Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, Massachusetts
e Northeastern University, Boston, Massachusetts
f Department of Dermatology, Harvard Medical School, Boston, Massachusetts
∗Correspondence to: Martina L. Porter, MD, Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS)Beth Israel Deaconess Medical Center330 Brookline AveBostonMA02215
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
| Funding sources: None. |
|
| Conflicts of interest: Dr Rosales Santillan has received fellowship funding from AbbVie and Janssen that went directly to her institution. Dr Her's spouse works for AbbVie. Dr Kimball is a consultant and investigator for AbbVie, Bristol Meyers Squibb, Janssen, Eli Lilly, Novartis, Pfizer, and UCB; a consultant for Kymera and AmirallInvestigator ChemoCentryx; receives fellowship funding from Janssen and AbbVie; served on the board of directors and served as president of the International Psoriasis Council; and served on the board of directors of the HS Foundation. Dr Porter is a consultant and investigator for UCB, Pfizer, Eli Lilly, and Novartis and an investigator for AbbVie, Janssen, and Bristol Meyers Squibb. Dr Holcomb and Authors Morss-Walton, Salian, and Giannotti have no conflicts of interest to declare. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 83 - N° 4
P. 1215-1218 - octobre 2020 Retour au numéro
Article précédent
- Applying to dermatology residency during the COVID-19 pandemic
- Donovan G. Kearns, Vipawee S. Chat, Shelley Uppal, Jashin J. Wu
- The presence and distribution of novel coronavirus in a medical environment
- Qianli Jiang, Yinghua Chen, Yingchun Dai, Shaoxi Cai, Guodong Hu
Bienvenue sur EM-consulte, la référence des professionnels de santé.